Pamela Young
Overview
Explore the profile of Pamela Young including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
214
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Crook Z, Sevilla G, Young P, Girard E, Phi T, Howard M, et al.
Nat Commun
. 2024 Oct;
15(1):8731.
PMID: 39384759
Many disease-causing proteins have multiple pathogenic mechanisms, and conventional inhibitors struggle to reliably disrupt more than one. Targeted protein degradation (TPD) can eliminate the protein, and thus all its functions,...
2.
Crook Z, Sevilla G, Young P, Girard E, Phi T, Howard M, et al.
bioRxiv
. 2024 May;
PMID: 38712232
Many disease-causing proteins have multiple pathogenic mechanisms, and conventional inhibitors struggle to reliably disrupt more than one. Targeted protein degradation (TPD) can eliminate the protein, and thus all its functions,...
3.
Mease P, Young P, Fallon L, Mundayat R, Dina O, Blachley T, et al.
Rheumatol Ther
. 2024 Jan;
11(2):313-329.
PMID: 38252211
Introduction: Randomized controlled trials have demonstrated tofacitinib efficacy for psoriatic arthritis (PsA); however, real-world effectiveness data are limited. This real-world analysis assessed baseline demographics/disease characteristics and tofacitinib effectiveness in patients...
4.
Mease P, Orbai A, FitzGerald O, Bedaiwi M, Fleishaker D, Mundayat R, et al.
Arthritis Res Ther
. 2023 Aug;
25(1):153.
PMID: 37608391
Background: Tofacitinib is an oral Janus kinase inhibitor for the treatment of psoriatic arthritis (PsA). This post hoc analysis assessed tofacitinib efficacy on enthesitis by baseline location and severity, and...
5.
Divoux J, Rolland S, Delille R, Levin C, Martin V, Young P, et al.
Eur J Immunol
. 2023 Apr;
53(6):e2250186.
PMID: 37056029
No abstract available.
6.
Orbai A, Mease P, Helliwell P, FitzGerald O, Fleishaker D, Mundayat R, et al.
BMC Rheumatol
. 2022 Aug;
6(1):68.
PMID: 36045453
Background: Tofacitinib is an oral Janus kinase inhibitor for the treatment of psoriatic arthritis (PsA). This post-hoc analysis of two phase III studies in patients with PsA treated with tofacitinib...
7.
Young P, Pinto D, Asher S, DeSanctis S, Gardner K, Geary S, et al.
West J Emerg Med
. 2022 Aug;
23(4):557-563.
PMID: 35980422
A healthcare workforce that demonstrates cultural competence and humility while reflecting the diversity of the surrounding community has the potential to significantly benefit the patient population it serves. In this...
8.
Mease P, Young P, Gruben D, Fallon L, Germino R, Kavanaugh A
Adv Ther
. 2022 Apr;
39(6):2932-2945.
PMID: 35482248
Introduction: This study characterized real-world demographic and baseline clinical characteristics, as well as treatment persistence and adherence, in patients with psoriatic arthritis (PsA) who had newly initiated tofacitinib treatment. Methods:...
9.
Taylor P, Bushmakin A, Cappelleri J, Young P, Germino R, Merola J, et al.
J Dermatolog Treat
. 2022 Apr;
33(5):2614-2620.
PMID: 35385361
Objectives: Evaluate relationships between changes in dermatologic assessments and quality of life (QoL) measures; quantify dermatologic symptom severity impacts on QoL in patients with psoriatic arthritis (PsA) treated with tofacitinib....
10.
McLeod K, Xavier J, Okhowat A, Williams S, Korchinski M, Young P, et al.
Int J Prison Health
. 2021 Oct;
18(1):43-54.
PMID: 34633774
Purpose: This study aims to describe knowledge of Canada's Good Samaritan Drug Overdose Act (GSDOA) and take home naloxone (THN) training and kit possession among people being released from provincial...